$NOVT

Glastra Matthijs sold $221K of NOVT

Glastra Matthijs (Chief Executive Officer) sold 1,301 shares of NOVANTA INC (NOVT) at $169.76 ($0.22M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glastra Matthijs
Published Jun 4, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NOVT
Neutral
medium confidence
Mentioned
$NOVT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NOVTNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not, by itself, change company fundamentals.

02

Market read

Insider selling can slightly weigh on sentiment, but 10b5-1 structure typically limits directional inference.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent buys/sales patterns or other company-specific news not present here.

Relevance 6/10Novelty 5/10Timing: Filed June 4; sale executed June 2 (post-trade disclosure).

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$NOVTNeutralMedium confidence
Context

Novanta CEO Glastra Matthijs sold 1,301 shares (~$220.9K) via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Limited, mostly sentiment-driven; expect muted price reaction unless paired with other catalysts.

Evidence & confidence

The filing is a routine 10b5-1 sale by a top executive; without additional operational/financial news, incremental impact is typically small.

Market effects

Minimal—single-company insider transaction without sector-wide information.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Novanta Inc

    Subject of the SEC Form 4 insider sale disclosure.

  • Glastra Matthijs

    Novanta CEO and director who sold shares.

Related articles

$NOVTHighAI 9/10

Novanta Announces Financial Results for the Second Quarter 2026

Novanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.

$NOVTHigh

NOVANTA INC (NOVT): Results of Operations and Financial Condition

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 novt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and

$NOVTMedAI 8/10

Novanta Completes Acquisition of Riverpoint Medical

Novanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.